BR0209033A - Construções e métodos para a expressão de proteìnas de envoltório de hcv recombinantes - Google Patents

Construções e métodos para a expressão de proteìnas de envoltório de hcv recombinantes

Info

Publication number
BR0209033A
BR0209033A BR0209033-3A BR0209033A BR0209033A BR 0209033 A BR0209033 A BR 0209033A BR 0209033 A BR0209033 A BR 0209033A BR 0209033 A BR0209033 A BR 0209033A
Authority
BR
Brazil
Prior art keywords
methods
proteins
wrap
signal peptide
expression
Prior art date
Application number
BR0209033-3A
Other languages
English (en)
Inventor
Erwin Sablon
Annie Van Broekhoven
Alfons Bosman
Erik Depla
Geert Deschamps
Original Assignee
Innogenetics Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innogenetics Nv filed Critical Innogenetics Nv
Publication of BR0209033A publication Critical patent/BR0209033A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/18—Togaviridae; Flaviviridae
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24223—Virus like particles [VLP]

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Communicable Diseases (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

"CONSTRUçõES E MéTODOS PARA A EXPRESSãO DE PROTEìNAS DE ENVOLTóRIO DE HCV RECOMBINANTES". A presente invenção relaciona-se aos vetores e aos métodos para a expressão eficiente de proteínas de envoltório de HCV em células eucarióticas. Mais particularmente, os ditos vetores compreendem a seq³ência de codificação para um peptídeo de sinal de lisozima aviário, ou um equivalente funcional do mesmo, unido a uma proteína de envoltório de HCV, ou uma parte da mesma. O dito peptídeo de sinal de lisozima aviário é removido eficientemente quando a proteína compreendendo o dito peptídeo de sinal de lisozima aviário unido a uma proteína de envoltório de HCV ou uma parte da mesma é expressa em uma célula eucariótica. As células eucarióticas adequadas incluem as células de leveduras, tais como as células de Saccharomyces ou de Hansenula.
BR0209033-3A 2001-04-24 2002-04-24 Construções e métodos para a expressão de proteìnas de envoltório de hcv recombinantes BR0209033A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP01870088 2001-04-24
US30560401P 2001-07-17 2001-07-17
PCT/BE2002/000062 WO2002085932A2 (en) 2001-04-24 2002-04-24 Constructs and methods for expression of recombinant hcv envelope proteins

Publications (1)

Publication Number Publication Date
BR0209033A true BR0209033A (pt) 2005-01-11

Family

ID=34072546

Family Applications (2)

Application Number Title Priority Date Filing Date
BR0209033-3A BR0209033A (pt) 2001-04-24 2002-04-24 Construções e métodos para a expressão de proteìnas de envoltório de hcv recombinantes
BR0209034-1A BR0209034A (pt) 2001-04-24 2002-04-24 Proteìnas de envoltório de hcv glicosiladas no núcleo

Family Applications After (1)

Application Number Title Priority Date Filing Date
BR0209034-1A BR0209034A (pt) 2001-04-24 2002-04-24 Proteìnas de envoltório de hcv glicosiladas no núcleo

Country Status (20)

Country Link
US (3) US7048930B2 (pt)
EP (3) EP1417298A2 (pt)
JP (2) JP4261195B2 (pt)
KR (1) KR100950104B1 (pt)
CN (1) CN1636050A (pt)
AR (3) AR035867A1 (pt)
AU (3) AU2002252856A1 (pt)
BR (2) BR0209033A (pt)
CA (3) CA2443740A1 (pt)
CZ (1) CZ20032853A3 (pt)
HU (1) HUP0303924A2 (pt)
MX (2) MXPA03009626A (pt)
NZ (2) NZ529324A (pt)
OA (1) OA13092A (pt)
PL (1) PL366621A1 (pt)
RU (1) RU2274643C2 (pt)
SK (1) SK13142003A3 (pt)
WO (3) WO2002086101A2 (pt)
YU (1) YU84103A (pt)
ZA (3) ZA200308274B (pt)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040185061A1 (en) * 1994-07-29 2004-09-23 Innogenetics N.V. Redox reversible HCV proteins with native-like conformation
EP1417298A2 (en) * 2001-04-24 2004-05-12 Innogenetics N.V. Core-glycosylated hcv envelope proteins
DE10143490C2 (de) * 2001-09-05 2003-12-11 Gsf Forschungszentrum Umwelt Rekombinantes MVA mit der Fähigkeit zur Expression von HCV Struktur-Antigenen
JP2006516955A (ja) * 2002-11-08 2006-07-13 イノジェネティックス・ナムローゼ・フェンノートシャップ Ｅ１ペプチド及びｎｓ３ペプチドを含むｈｃｖワクチン組成物
US7439042B2 (en) * 2002-12-16 2008-10-21 Globeimmune, Inc. Yeast-based therapeutic for chronic hepatitis C infection
JP4371739B2 (ja) * 2003-09-02 2009-11-25 株式会社東芝 シリアルａｔａインタフェースを持つ電子機器及びシリアルａｔａバスのパワーセーブ方法
EP1574517A1 (en) * 2004-03-09 2005-09-14 Innogenetics N.V. HCV E1 comprising specific disulfide bridges
EP1602664A1 (en) * 2004-03-08 2005-12-07 Innogenetics N.V. HCV E1 comprising specific disulfide bridges
JP4885476B2 (ja) * 2004-05-21 2012-02-29 株式会社日本触媒 タンパク質及び／又はペプチドの細胞内導入方法
AU2011254055B2 (en) * 2004-10-18 2012-12-20 Globeimmune, Inc. Yeast-based therapeutic for chronic hepatitis C infection
AU2005295317B2 (en) * 2004-10-18 2011-10-13 Globeimmune, Inc. Yeast-based therapeutic for chronic hepatitis C infection
US20060234360A1 (en) * 2005-04-13 2006-10-19 Paola Branduardi Ascorbic acid production from D-glucose in yeast
US9216212B2 (en) 2005-08-05 2015-12-22 University Of Massachusetts Virus-like particles as vaccines for paramyxovirus
US7951384B2 (en) * 2005-08-05 2011-05-31 University Of Massachusetts Virus-like particles as vaccines for paramyxovirus
AR058140A1 (es) * 2005-10-24 2008-01-23 Wyeth Corp Metodo de produccion proteica utilizando compuestos anti-senescencia
EP2027271A4 (en) * 2006-05-19 2010-06-09 Glycofi Inc RECOMBINANT VECTORS
AU2015234338C1 (en) * 2006-07-28 2017-07-20 The Trustees Of The University Of Pennsylvania Improved vaccines and methods for using the same
AU2007288129B2 (en) * 2006-08-25 2013-03-07 The Macfarlane Burnet Institute For Medical Research And Public Health Limited Recombinant HCV E2 glycoprotein
US8728489B2 (en) 2008-09-19 2014-05-20 Globeimmune, Inc. Immunotherapy for chronic hepatitis C virus infection
US8580270B2 (en) 2008-09-30 2013-11-12 University Of Massachusetts Respiratory synctial virus (RSV) sequences for protein expression and vaccines
US20100104555A1 (en) * 2008-10-24 2010-04-29 The Scripps Research Institute HCV neutralizing epitopes
DE102009044224A1 (de) * 2009-10-09 2011-04-28 PomBio Tech GmbH Starterzentrum der Universität des Saarlandes Campus Geb. A1-1 Methode zur Produktion von HCV Virus-ähnlichen Partikeln
MX345854B (es) 2010-12-22 2017-02-17 Bayer Ip Gmbh Respuesta inmune potenciada en la especie bovina.
US20140155469A1 (en) 2011-04-19 2014-06-05 The Research Foundation Of State University Of New York Adeno-associated-virus rep sequences, vectors and viruses
EP3590950A1 (en) 2011-05-09 2020-01-08 Ablynx NV Method for the production of immunoglobulin single varible domains
CA2940794C (en) 2014-02-28 2022-05-31 Bayer Animal Health Gmbh Immunostimulatory plasmids
WO2017081520A1 (en) * 2015-11-13 2017-05-18 Mammedov Tarlan Production of in vivo n-deglycosylated recombinant proteins by co-expression with endo h
EP3184642B1 (de) * 2015-12-22 2019-05-08 bisy e.U. Hefezelle
EP3515483A4 (en) 2016-09-21 2020-12-16 The Governors of the University of Alberta HEPATITIS C VIRUS IMMUNOGENIC COMPOSITIONS AND THEIR USE PROCEDURES

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4395395A (en) 1979-05-21 1983-07-26 The United States Of America As Represented By The Department Of Health And Human Services Detection of non-A, non-B hepatitis associated antigen
EP0288198A3 (en) 1987-04-20 1989-03-29 Takeda Chemical Industries, Ltd. Production of peptide
US5135854A (en) * 1987-10-29 1992-08-04 Zymogenetics, Inc. Methods of regulating protein glycosylation
US5350671A (en) 1987-11-18 1994-09-27 Chiron Corporation HCV immunoassays employing C domain antigens
US5698390A (en) 1987-11-18 1997-12-16 Chiron Corporation Hepatitis C immunoassays
US5683864A (en) 1987-11-18 1997-11-04 Chiron Corporation Combinations of hepatitis C virus (HCV) antigens for use in immunoassays for anti-HCV antibodies
JP2791418B2 (ja) * 1987-12-02 1998-08-27 株式会社ミドリ十字 異種蛋白質の製造方法、組換えｄｎａ、形質転換体
NO177065C (no) * 1988-09-26 1995-07-12 Labofina Sa Framgangsmåte for framstilling av enzymatisk aktivt humant lysozym
US5747239A (en) 1990-02-16 1998-05-05 United Biomedical, Inc. Synthetic peptides specific for the detection of antibodies to HCV, diagnosis of HCV infection and preventions thereof as vaccines
US5712087A (en) 1990-04-04 1998-01-27 Chiron Corporation Immunoassays for anti-HCV antibodies employing combinations of hepatitis C virus (HCV) antigens
WO1992001800A1 (en) * 1990-07-20 1992-02-06 Chiron Corporation Method for integrative transformation of yeast using dispersed repetitive elements
CA2047792C (en) 1990-07-26 2002-07-02 Chang Y. Wang Synthetic peptides specific for the detection of antibodies to hcv, diagnosis of hcv infection and prevention thereof as vaccines
ES2188583T3 (es) 1991-06-24 2003-07-01 Chiron Corp Polipeptidos para el virus de la hepatitis c (hcv).
WO1994001132A1 (en) 1992-07-07 1994-01-20 Merck & Co., Inc. VACCINE COMPRISING MIXED preS1+preS2+S AND CORE PARTICLE
DK0992580T3 (da) 1993-11-04 2005-07-11 Innogenetics Nv Epitoper på human T-celler, som er immundominante for hepatitis C-virus
DK0721505T4 (da) * 1994-07-29 2006-08-14 Innogenetics Nv Rensede hepatitis C-virus-kappeproteiner til diagnostisk og terapeutisk anvendelse
ZA9610456B (en) * 1995-12-20 1997-06-20 Novo Nordisk As N-terminally extended proteins expressed in yeast
US5935824A (en) * 1996-01-31 1999-08-10 Technologene, Inc. Protein expression system
EP0946735B1 (en) * 1996-12-20 2006-02-08 Novo Nordisk A/S N-terminally extended proteins expressed in yeast
WO1999024466A2 (en) 1997-11-06 1999-05-20 Innogenetics N.V. Multi-mer peptides derived from hepatitis c virus envelope proteins for diagnostic use and vaccination purposes
EP1049790A1 (en) * 1998-01-23 2000-11-08 Novo Nordisk A/S Process for making desired polypeptides in yeast
ATE278960T1 (de) 1998-04-17 2004-10-15 Innogenetics Nv Verbessertes immundiagnostische tests durch verwendung von reduzierende agenzien
EP1090033B2 (en) 1998-06-24 2007-12-19 Innogenetics N.V. Particles of hcv envelope proteins: use for vaccination
AU1144501A (en) 1999-10-27 2001-05-08 Innogenetics N.V. Redox reversible hcv proteins with native-like conformation
TR200202169T1 (tr) 2001-01-11 2004-06-21 Innogenetics N.V. Tanı ve tedavide kullanım için pürifiye hepatit C virüsü zarf proteinleri.
EP1417298A2 (en) 2001-04-24 2004-05-12 Innogenetics N.V. Core-glycosylated hcv envelope proteins
KR20040076869A (ko) 2001-12-18 2004-09-03 인노제네틱스 엔. 브이. 진단적 및 치료적 용도를 위한 정제된 ｃ형 간염 바이러스외피 단백질
JP2006516955A (ja) 2002-11-08 2006-07-13 イノジェネティックス・ナムローゼ・フェンノートシャップ Ｅ１ペプチド及びｎｓ３ペプチドを含むｈｃｖワクチン組成物

Also Published As

Publication number Publication date
OA13092A (en) 2006-11-10
AU2002308449B2 (en) 2008-05-29
SK13142003A3 (en) 2004-11-03
EP1381671A2 (en) 2004-01-21
ZA200308274B (en) 2005-01-24
CN1636050A (zh) 2005-07-06
US20030211597A1 (en) 2003-11-13
EP1417298A2 (en) 2004-05-12
KR100950104B1 (ko) 2010-03-30
AU2002257392B2 (en) 2007-05-10
AR035869A1 (es) 2004-07-21
CZ20032853A3 (cs) 2004-08-18
ZA200308277B (en) 2004-07-08
AU2002252856A1 (en) 2002-11-05
CA2443740A1 (en) 2002-10-31
WO2002086101A3 (en) 2004-02-19
JP2004532029A (ja) 2004-10-21
AR035868A1 (es) 2004-07-21
WO2002086100A3 (en) 2004-02-19
US20030152940A1 (en) 2003-08-14
US7314925B2 (en) 2008-01-01
MXPA03009626A (es) 2004-06-30
PL366621A1 (en) 2005-02-07
CA2444006A1 (en) 2002-10-31
ZA200308272B (en) 2005-01-24
WO2002085932A3 (en) 2003-03-13
BR0209034A (pt) 2005-02-01
KR20030094359A (ko) 2003-12-11
CA2443781A1 (en) 2002-10-31
NZ529019A (en) 2004-05-28
NZ529324A (en) 2005-08-26
US7048930B2 (en) 2006-05-23
MXPA03009632A (es) 2004-06-30
JP4261195B2 (ja) 2009-04-30
WO2002085932A2 (en) 2002-10-31
JP2004536052A (ja) 2004-12-02
WO2002086101A2 (en) 2002-10-31
RU2274643C2 (ru) 2006-04-20
HUP0303924A2 (hu) 2004-03-01
EP1414942A2 (en) 2004-05-06
YU84103A (sh) 2006-05-25
AR035867A1 (es) 2004-07-21
JP4173741B2 (ja) 2008-10-29
US7238356B2 (en) 2007-07-03
US20030108561A1 (en) 2003-06-12
WO2002086100A2 (en) 2002-10-31
RU2003130955A (ru) 2005-04-20

Similar Documents

Publication Publication Date Title
BR0209033A (pt) Construções e métodos para a expressão de proteìnas de envoltório de hcv recombinantes
WO2005017149A8 (en) Compositions and methods for enhanced expression of recombinant polypeptides from a single vector using a peptide cleavage site
PL372849A1 (en) Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins
ATE546533T1 (de) Rekombinante expression von proteinen in einer disulfidverbrückten, zweikettigen form
CA2089094A1 (en) Expression of recombinant polypeptides with improved purification
ATE277947T1 (de) Antitumorale zusammenstellung von immunogene polypetiden mit veränderter zellokalisierung
BR0009392A (pt) Polipeptìdeo, sequência de ácido nucleico, vetor de expressão recombinante, célula hospedeira recombinante, métodos para produzir uma sequência de ácido nucleico mutante e para produzir um polipeptìdeo, mutante de um polipeptìdeo com atividade de alafa-amilase, e, uso do polipeptìdeo ou variante
ES2171398T3 (es) Acidos nucleicos viricos vegetales recombinantes.
DE59711812D1 (de) Rekombinante collagenase typ i aus clostridium histolyticum und ihre verwendung zur isolierung von zellen und zellverbänden
KR900018373A (ko) 재조합 바쿨로바이러스, 이 바이러스를 사용하는 일본 뇌염바이러스의 외포 단백질 및 그 단백질의 제조방법.
BR9815551A (pt) Vacina de envoltório dimérica recombinante contra infecção flaviviral
BR9713242A (pt) Encapsulamento de polipeptìdeos dentro da matriz de amido
AR012499A1 (es) Una secuencia quimerica de acido nucleico que codifica una proteina de fusion, un vector de expresion que comprende dicha secuencia quimerica, una celula huesped transformada que contiene dicho vector, la proteina de fusion obtenida y un metodo in vitro para la preparacion de un polipeptido recombin
DE69735242D1 (de) N-terminal verlängerte proteine exprimiert in hefe
NO992158L (no) Nukleinsyre- og aminosyresekvenser forbundet med Heliobacter Pylori og vaksinepreparater av disse.
ATE461280T1 (de) Rekombinante allergene aus der dörrobstmotte plodia interpunctella
ATE85648T1 (de) Fuer ein lytisch wirksames, chimaeres protein kodierende rekombinante dna und ihre verwendung.
Giuffrida et al. Human as1-casein like protein: purification and N-terminal sequence determination
WO2022208554A3 (en) Constructs and methods for increased expression of polypeptides
AP2003002886A0 (en) Constructs and methods for expression of recombinant HCV envelope proteins
Fujiwara et al. Basement membrane collagen from bovine lung: its chain associations as observed by two-dimensional electrophoresis
WO2003057708A3 (en) Fusion proteins
ATE512162T1 (de) Antikörper gegen das p51 protein
WO2000002909A3 (en) Amphiphilic peptides derived from the cytoplasmic tail of viral envelope proteins
WO2002012475A3 (en) C1q-related factor, homologous polypeptides and therapeutic uses thereof

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A(S) 8A E 9A ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2103 DE 26/04/2011.